CTI-1601
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Friedreich Ataxia
Conditions
Friedreich Ataxia
Trial Timeline
Sep 21, 2022 → Dec 4, 2023
NCT ID
NCT05579691About CTI-1601
CTI-1601 is a phase 2 stage product being developed by Larimar Therapeutics for Friedreich Ataxia. The current trial status is completed. This product is registered under clinical trial identifier NCT05579691. Target conditions include Friedreich Ataxia.
What happened to similar drugs?
0 of 9 similar drugs in Friedreich Ataxia were approved
Approved (0) Terminated (0) Active (9)
Hype Score Breakdown
Clinical
12
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06447025 | Phase 2 | Recruiting |
| NCT05579691 | Phase 2 | Completed |
Competing Products
20 competing products in Friedreich Ataxia